tokyo

Casio to Release G-SHOCK with Minimalist Metal Design and Even Better Fit

Reconstructed Shock-Resistant Structure and Streamlined Exterior TOKYO, Oct. 28, 2025 /PRNewswire/ -- Casio Computer Co., Ltd. announced today the release…

2 months ago

Total Investment of Approx. USD 11.6 Million in TB and NTD R&D Projects With Partners Including Fujifilm, Stop TB Partnership, and the Ohio State University

TOKYO, Oct. 29, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.73…

2 months ago

Health Canada Grants Authorization for LEQEMBI (lecanemab) for the Treatment of Early Alzheimers Disease

In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or…

2 months ago

Updated IOC report shows 86 per cent of all permanent Olympic venues still in use

23 October 2025 - An updated analysis of venues shows that 86 per cent of all permanent venues used at the…

3 months ago

Casio to Release Ring-Sized G-SHOCK

Shock-Resistant Structure and 200-Meter Water Resistance Packed in Smallest Size in Brand's History TOKYO, Oct. 20, 2025 /PRNewswire/ -- Casio…

3 months ago

ESR and Colt DCS Announce Joint Venture on New Osaka Data Centre Development

TOKYO, Oct. 16, 2025 /PRNewswire/ -- ESR, an Asia-Pacific ("APAC") focused real asset owner and manager, and Colt Data Centre…

3 months ago

Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases

Hinge Bio to receive $10 million upfront and is eligible to receive $95 million for the SLE indication and additional…

3 months ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

September 29, 2025 19:30 ET  | Source: Nxera Pharma Tokyo, Japan and Cambridge and London, UK, 30 September 2025 –…

3 months ago

LEQEMBI (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimers Disease Approved in China

September 28, 2025 19:30 ET  | Source: Biogen Inc. TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai…

3 months ago

Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY (Piflufolastat F 18) in Japan

BEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc.  (NASDAQ: LNTH) and GE HealthCare…

4 months ago